Abstract Details

Title Sumatriptan and Dihydroergotamine in Distal Human Isolated Coronary Arteries

Topic Headache

Presentation(s) P06 - (-)

Poster/Presentation
Number 156

Objective

Background BACKGROUND: Sumatriptan and dihydroergotamine (DHE) are both 5-HT receptor agonists and two of the most widely used drugs for the acute treatment of migraine. These drugs are contra-indicated in people with cardiovascular disease because of their vasoconstricting properties, as has previously been assessed in proximal coronary arteries. The effect of DHE in distal coronary arteries, however, has never been reported, although smaller coronary arteries might also account for angina-like symptoms, especially in women.

Design/Methods DESIGN/METHODS: Segments of proximal (o 3-5 mm) and distal (o 0.5-1 mm) human isolated coronary arteries were mounted in organ baths and concentration response curves for sumatriptan and DHE were constructed.

Results RESULTS: In proximal coronary artery segments, maximal contractions to sumatriptan (16+/-18% of contraction to 100 mM KCl) and DHE (5+/-4%) were not significantly different. In contrast, in distal coronary arteries, the contractile responses to sumatriptan (18+/-11%) were significantly larger than those to DHE (4+/-2%). At clinically relevant concentrations (Cmax after different formulations), contractions to both sumatriptan and DHE in proximal as well as distal coronary arteries were below 6%.

Conclusions CONCLUSIONS: Our results indicate that coronary artery contractions to DHE in distal coronary artery are smaller than those to sumatriptan, although in the clinical situation both drugs are likely to induce only a slight contraction.

Authors/Disclosures
Antoinentte Maassen Van Den Brink, PhD (Erasmus Medical Center Rotterdam) PRESENTER	Antoinentte Maassen Van Den Brink, PhD has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Antoinentte Maassen Van Den Brink, PhD has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Lilly. Antoinentte Maassen Van Den Brink, PhD has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Teva. The institution of Antoinentte Maassen Van Den Brink, PhD has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Springer. The institution of Antoinentte Maassen Van Den Brink, PhD has received research support from Novartis.
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
Jack P. Antel, MD, FAAN (Montreal Neurologic Hospital)	Dr. Antel has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for sanofi, roche, biogen, wave,nervgen. The institution of Dr. Antel has received research support from Novartis canada bristol myers squib. Dr. Antel has a non-compensated relationship as a past president with ACTRIMS that is relevant to AAN interests or activities.

��ɫ��

��ɫ��